XML 47 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)
3 Months Ended 12 Months Ended 41 Months Ended
Aug. 03, 2012
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2015
Related Party Transaction [Line Items]        
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures $ 6,000,000   $ 6,000,000 $ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares) 600,000      
Joint Venture Method Investment Ownership Percentage 60.00%      
Joint Venture Investments In Non Voting Preferred Ownership Units 5,000,000      
Joint Venture Investments Common Ownership Units, Co-venture (in shares) 400,000      
Ownership Percentage Co-venture 40.00%      
Percentage Of Royalty Payment 3.00%      
Development Activities Monthly Fee $ 63,000      
Accounting and Administrative Monthly Fee $ 1,000      
Joint Venture, Operating Expenses, Inter Company Transactions     959,000 7,194,000
Joint Venture, Operating Expenses Allocated To Company     959,000 6,527,000
Percentage Of Non Royalty Income 5.00%      
Reduced Monthly Management Fee $ 35,000      
Service Management Costs   $ 150,000    
Revolving Credit Facility [Member]        
Related Party Transaction [Line Items]        
Line of Credit Facility, Maximum Borrowing Capacity     1,400,000 1,400,000
Long-term Line of Credit     1,510,000 1,510,000
Common Stock [Member]        
Related Party Transaction [Line Items]        
Joint Venture Losses Recognition Criteria, Common Ownership Equity     $ 0 $ 0
Noncontrolling Interest, Ownership Percentage by Parent     60.00% 60.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners     40.00% 40.00%
Preferred Stock [Member]        
Related Party Transaction [Line Items]        
Noncontrolling Interest, Ownership Percentage by Parent     100.00% 100.00%
Noncontrolling Interest [Member]        
Related Party Transaction [Line Items]        
Noncash or Part Noncash Acquisition, Other Liabilities Assumed     $ 667,000  
Exclusive License Agreement [Member]        
Related Party Transaction [Line Items]        
Annual Maintenance Payments 25,000      
Exclusive License Agreement [Member] | Maximum [Member]        
Related Party Transaction [Line Items]        
Milestone Payments 500,000      
Royalty Expense 1,000,000      
Exclusive License Agreement [Member] | Minimum [Member]        
Related Party Transaction [Line Items]        
Milestone Payments 50,000      
Royalty Expense 500,000      
Lipimetix [Member]        
Related Party Transaction [Line Items]        
Noncash or Part Noncash Acquisition, Other Liabilities Assumed     667,000  
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed), Total 378,000   $ 378,000  
Voting Common Ownership Units [Member]        
Related Party Transaction [Line Items]        
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 1,000,000      
Non Voting Preferred Ownership Units [Member]        
Related Party Transaction [Line Items]        
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures $ 5,000,000